Sumitomo Chemical Company, Limited

Takeda Chemical Industries, Inc.

Dainippon Ink and Chemicals, Incorporated

Hisamitsu Pharmaceutical Company, Inc.

Eisai Company, Limited

Takeda Pharmaceutical Company Limited

Japan Atomic Energy Agency

Daiei Chemical Co., Ltd.

Sumika Fine Chemical Company, Ltd.

Yasuyuki Suzuki

Katsumi Iga

Yukihiro Matsumoto

Toshio Nakamatsu

Yasuyuki Watanabe

Takako Yoshiba

Yoshitugu Egashira

Takashi Omura

Takehiko Naka

Hiroaki Okada

Tatsuo Watanabe

Yoshiyuki Ono

Yasuhiro Funahashi

Masayuki Matsukura

Akihiko Tsuruoka

Keiko Takahashi

Yasuhiro Kuwana

Isa Nishiyama

Yoshiaki Hayashi

Kazuki Miyazaki

Tomohiro Matsushima

Yuji Yamamoto

Yasunari Maekawa

Hiroshi Obaishi

Toru Haneda

Junji Matsui

Muneo Nonomura

Hisakazu Tanaka

Hisatomo Yonehara

Yoshio Fukuda

Kazuhide Ashizawa

Junichi Kamata

Masahiko Tsujii

Naohito Saito

Hiroyuki Chiba

Taiju Nakamura

Masao Nishikuri

Hitoshi Hayakawa

Hisayoshi Shimizu

Kiyoyasu Hashimoto

Akio Kayano

Masayuki Yamada

Shin Hasegawa

Itaru Arimoto

Atsumi Yamaguchi

Katsuji Nakamura

Taizo Ohshima

Fusayo Mimura

Shin Sakurai

Hiroyuki Ishizuka

Hiroyuki Saito

Ikuo Kushida

Masahiro Sakurai

Eiichi Yamamoto

Ken-ichi Nomoto

Sachi Suzuki

Kunio Yamada

Jyoji Kawamura

Kenji Matsui

Astsushi Koiwa

Masahiro Kawase

Shigeru Juzu

Hiroyuki Okazaki

Provision of, and a method for production of, a polymer electrolyte membrane, which is characterized by introducing a vinyl monomer into an aromatic polymer membrane substrate, typified by polyether ether ketone, polyether imide, or polysulfone, as graft chains by graft polymerization, and then chemically converting some of the graft chains or/and part of the aromatic polymer chain into sulfonic groups.

Polymer electrolyte membrane composed of aromatic polymer membrane base and method for producing the same

A polymerizable liquid crystal composition includes a liquid crystal compound having a polymerizable group, wherein the composition includes from 0.1 to 6.0% by weight of a (meth)acrylic copolymer (H), which 

Polymerizable liquid crystal composition and optically anisotropic medium

The present invention provides a percutaneous absorption preparation which comprises a compound having angiotensin II antagonistic activity and which allows the compound to permeate through the skin at a desirable rate for a prolonged period.

Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

Compounds represented by the following general formula: [wherein Ais an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xis &#x2014;O&#x2014;, &#x2014;S&#x2014;, etc.; Yis an optionally substituted Caryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tis a group represented by the following general formula: (wherein Eis a single bond or &#x2014;N(R)&#x2014;, Rand Reach independently represent a hydrogen atom, an optionally substituted Calkyl group, etc. and Zrepresents a Calkyl group, a Calicyclic hydrocarbon group, a Caryl group, etc.)],

Nitrogen-containing aromatic derivatives

A negative-working CTP plate which is superior in resolution and printing resistance of the image area of a press plate is provided, which is obtained by forming a latent image on a heat-sensitive layer in a heat-sensitive lithographic printing plate comprising a substrate having a hydrophilic surface and a heat-sensitive layer made of an alkali-soluble polymer formed on the surface of the substrate, using heat generated upon irradiation with laser light, and developing the heat-sensitive layer using an alkaline developing solution. In the heat-sensitive lithographic printing plate comprising a substrate having a hydrophilic surface, and a heat-sensitive layer made of an alkali-soluble polymer formed on the surface of the substrate, an advancing contact angle (&#x3b8;) of the surface of the heat-sensitive layer with water at 25&#xb0; C. is within a range from 70&#xb0; to 110&#xb0;, a receding contact angle (&#x3b8;) of the surface of the heat-sensitive layer with water at 25&#xb0; C. after heating at 150&#xb0; C. for 3 minutes is larger than a receding contact angle (&#x3b8;) of the surface of the heat-sensitive layer with water at 25&#xb0; C. before heating, and a difference in receding contact angle before and after heating, (&#x3b8;&#x2212;&#x3b8;), is larger than 1&#xb0; and is smaller than 40&#xb0;.

Heat-sensitive lithographic printing plate and image forming method

The present invention provides carbapenem hydrochloride trihydrate crystals, which are chemically stable, easily purified and useful as antimicrobial agents, a process for producing them, and a powdery charged preparation for injection containing them. That is, it provides carbapenem hydrochloride trihydrate crystals having a powdery X-ray diffraction pattern containing lattice distances (d) of 9.0, 4.1 and 2.8 &#x212b;, a process for producing them, and a powdery charged preparation for injection containing them.

Carbapenem compound crystals and interjection preparations

Iontophoresis method

To provide a practical matrix for iontophoresis with markedly improved drug availability. A system for iontophoreses, which comprises an anode side matrix and a cathode side matrix, wherein the anode side matrix contains a cationized drug and the cathode side matrix contains a water soluble acidic substance. A matrix for iontophoreses comprising a drug reservoir containing a drug, the drug reservoir having a thickness of less than 0.05 mm. Iontophoresis using the iontophoretic matrix of the present invention makes it possible to administer a drug to the body at high availability.

Matrix for iontophoreses

A drug held or supported by an interface comprising a porous matrix is dissolved with a drug dissolution liquid containing a humectant, and the drug is transdermally delivered by iontophoresis. The humectant includes e.g. glycerin and other polyhydric alcohols, sugar alcohols, proline and other amino acids and acidic mucopolysaccharides. The concentration of the humectant may be about 1 to 50% by weight, and the concentration of proline or other amino acid or its salt may be about 1 to 30% by weight. The drug includes (1) a physiologically active peptide or protein with a molecular weight of 100 to 30,000 or (2) a nonpeptide physiologically active compound with a molecular weight of 100 to 1,000.

Dissolution liquid for drug in iontophoresis

The present invention concerns an aqueous resin dispersion comprising a copolymer of a perfluoroalkyl group-containing ethylenically unsaturated monomer and/or polydimethylsiloxane group-containing ethylenically unsaturated monomer and another ethylenically unsaturated monomer copolymerizable therewith dispersed in water in the presence of a water-dispersible polyurethane containing a polydimethylsiloxane group such as silicone and a hydrophilic group such as a carboxylate group. The aqueous resin dispersion of the present invention provides a release agent which can freely control releasability, be excellent in adhesion to a substrate, and undergo little migration to back face or little change in releasability with time.

Aqueous resin dispersion and process for the preparation thereof

An anthrapyridone compound of the following formula (I) and which is useful for coloring resins: ##STR1## wherein X.sup.1 is hydrogen, --NHCOR.sup.1, --CONR.sup.2 R.sup.3, --COR.sup.4, --SO.sub.2 R.sup.5 or --SO.sub.2 NR.sup.6 R.sup.7, in which R.sup.1 and R.sup.4 are each C.sub.1-4 alkyl, R.sup.2 and R.sup.3 are each hydrogen or C.sub.1-4 alkyl, R.sup.5 is C.sub.1-4 alkyl or hydroxyethyl, R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl, X.sup.2 is hydrogen or imidomethyl of the formula (II): ##STR2## wherein n is a number of 1 to 2, X.sup.4 is hydrogen or carboxylic acid C.sub.1-4 alkyl-ester, X.sup.3 is hydrogen, halogen, hydroxyl, C.sub.1-4 alkyl or C.sub.1-4 alkoxyl, with the proviso that X.sup.1 is --NHCOR.sup.1, --CONR.sup.2 R.sup.3, --COR.sup.4, --SO.sub.2 R.sup.5 or --SO.sub.2 NR.sup.6 R.sup.7 when X.sup.2 is hydrogen, X.sup.2 is the imidomethyl of the formula (II) when X.sup.1 is the hydrogen, is provided, which is prepared by allowing an .alpha.-haloanthraquinone compound with an acylated primary aromatic amine compound in a nonaqueous medium in the presence of metallic copper or a copper compound.

Anthrapyridone compounds, their production process and their use

The hydrogel of the invention contains polyvinyl alcohol (a hydrogel support), and a high water-absorbent resin and/or a hydrophilic high molecular compound, which are capable of containing a large amount of water. The rate of evaporation of water from this hydrogel is slow. The hydrogel retains water for a long time and releases an active ingredient gradually. The hydrogel containing a pharmacologically active substance is useful as a pharmaceutical preparation.

Hydrogel

An anthrapyridone compound of the following formula (I) and which is useful for coloring resins: ##STR1## wherein X.sup.1 is hydrogen, --NHCOR.sup.1, --CONR.sup.2 R.sup.3, --COR.sup.4, --SO.sub.2 R.sup.5 or --SO.sub.2 NR.sup.6 R.sup.7, in which R.sup.1 and R.sup.4 are each C.sub.1-4 alkyl, R.sup.2 and R.sup.3 are each hydrogen or C.sub.1-4 alkyl, R.sup.5 is C.sub.1-4 alkyl or hydroxyethyl, R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl, X.sup.2 is hydrogen or imidomethyl of the formula (II): ##STR2## wherein n is a number of 1 to 2, X.sup.4 is hydrogen or carboxylic acid C.sub.1-4 alkyl-ester, X.sup.3 is hydrogen, halogen, hydroxyl, C.sub.1-4 alkyl or C.sub.1-4 alkoxyl, with the proviso that X.sup.1 is --NHCOR.sup.1, --CONR.sup.2 R.sup.3, --COR.sup.4, --SO.sub.2 R.sup.5 or --SO.sub.2 NR.sup.6 R.sup.7 when X.sup.2 is hydrogen, X.sup.2 is the imidomethyl of the formula (II) when X.sup.1 is the hydrogen, is provided, which is prepared by allowing the .alpha.-halonathraquinone compound with an acylated primary aromatic amine compound in a nonaqueous medium in the presence of metallic copper or a copper compound.

Anthrapyridone compounds

The present invention concerns a sustained-release microcapsule preparation comprising an ion exchange resin with 6 to 16% crosslinking, containing a drug adsorbed in an amount not less than 80% of its theoretical ion adsorption amount and coated with a water-permeable polymer.

Sustained-release preparation and production thereof

Growing community of inventors

Osaka, Japan

Yasuyuki Suzuki